Antibody Information
General Information of This Antibody
| Antibody ID | ANI0KGAKJ |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | MMUC3333A |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | Mucin-16 (MUC16) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
RG7882 [Phase 1 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Progression Free Survival |
5.8 months
|
|||
| Patients Enrolled |
Eligible patients include those with MUC16+ ovarian/pancreatic cancers (ECOG 0-1, measurable disease) who progressed after 1-2 prior therapies, excluding those with recent anti-tumor therapy, MUC16/MMAE-targeted treatment, active infections, uncontrolled comorbidities, CNS metastases, or Grade >1 toxicities from prior treatment.
|
||||
| Administration Dosage |
DMUC4064A will be administered to participants at a starting dose of 1.0 milligram per kilogram (mg/kg) by IV infusion q3w and would be monitored for DLTs for 21 days after first infusion of Cycle 1 (cycle length=21 days).
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02146313 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase I, Open-Label, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of DMUC4064A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
|
||||
| Primary Endpoint |
The study evaluates dose-limiting toxicities (DLTs) during Cycle 1 (21 days) to determine maximum tolerated dose (MTD) and recommended Phase II dose of DMUC4064A, while monitoring adverse events (AEs/SAEs) over approximately 3.5 years.
|
||||
| Other Endpoint |
Key outcomes include immunogenicity (anti-DMUC4064A antibodies), pharmacokinetic profile, objective response rate (RECIST v1.1), duration of response, and progression-free survival in platinum-resistant ovarian cancer and unresectable pancreatic cancer patients over 3.5 years.
|
||||
References